CanSino Wins Priority Review for First Adult DTaP Booster in China

CanSino Biologics, Inc. Class H ( (HK:6185) ) just unveiled an announcement.

CanSino Biologics said China’s Center for Drug Evaluation under the National Medical Products Administration has granted priority review status to its new drug application for a tetanus, reduced diphtheria and acellular pertussis five-component combined vaccine for people aged six and above. The firm is preparing to submit the application, which, if approved, would introduce China’s first booster vaccine for adolescents and adults targeting these diseases, filling a domestic market gap and complementing its already approved infant DTaP product.

The new Td5cp Adolescent and Adult vaccine is designed as a booster shot with two additional pertussis antigen components compared with CanSino’s three-component infant formulation, aiming to enhance antigen coverage and stabilize product quality. Priority review is expected to accelerate regulatory assessment by focusing resources on this filing, potentially strengthening CanSino’s position in the vaccine market and offering investors a new growth driver if the product successfully launches.

The most recent analyst rating on (HK:6185) stock is a Buy with a HK$64.00 price target. To see the full list of analyst forecasts on CanSino Biologics, Inc. Class H stock, see the HK:6185 Stock Forecast page.

More about CanSino Biologics, Inc. Class H

CanSino Biologics Inc. is a China-based biopharmaceutical company specializing in the research, development and commercialization of innovative vaccines. The company focuses on advanced vaccine platforms to meet unmet public health needs in both pediatric and adult immunization markets.

Average Trading Volume: 750,058

Technical Sentiment Signal: Sell

Current Market Cap: HK$12.34B

For a thorough assessment of 6185 stock, go to TipRanks’ Stock Analysis page.